Hövelmann U et al. Diabetes 2020;69(Suppl 1):237-OR;
Nishimura E et al. Diabetes 2020;69(Suppl 1):236-OR.
HSB has received speaker’s fees from AstraZeneca, Eli Lilly, Janssen, Merck and Novo Nordisk, and research funding from Amgen, AstraZeneca, Boehringer Ingelheim, Ceapro, Eli Lilly, Gilead, Janssen, Kowa, Madrigal, Merck, Novo Nordisk, Sanofi and Tricida.
JR has received research support from Eli Lilly, Genentech, GlaxoSmithKline, Intarcia, Janssen, Merck, Novo Nordisk, Oramed, Pfizer and Sanofi. JI, AG and KS are employees of Novo Nordisk.
This study was funded by Novo Nordisk. Medical writing support was provided by Dr Nicolas Bertheleme of Oxford PharmaGenesis, Oxford, UK, with funding from Novo Nordisk.
Presented at the European Association for the Study of Diabetes (EASD) Annual Meeting, virtual format, 21–25 September 2020.